By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Diffusion Pharmaceuticals 

2020 Avon Court, Suite 4

Charlottesville  Virginia  22902  U.S.A.
Phone: 434-220-0718 Fax: 434-220-0722


SEARCH JOBS


Industry
Pharmaceutical

Segment
Drug Discovery





Company News
Diffusion Pharma Successfully Completes Animal Toxicity Studies In Preparation For Phase III Pivotal Trial Of TSC In New Diagnosed Glioblastoma Patients 9/19/2016 8:36:35 AM
Diffusion Pharma To Present At 18th Annual Rodman & Renshaw Global Investment Conference 9/9/2016 7:30:35 AM
Diffusion Pharma Announces Reverse Stock Split In Preparation For Proposed Uplisting To NASDAQ Capital Market 8/18/2016 7:58:46 AM
Diffusion Pharma Announces Acceptance Of Abstract On Use Of TSC In Hypoxia Driven Medical Emergencies At ACEP 2016 Research Forum 7/6/2016 7:50:52 AM
RestorGenex (RESX) and Diffusion Pharma Merge to Form Wholly-Owned Oncology Subsidiary 12/28/2015 7:20:50 AM
Diffusion Pharmaceuticals To Present At Cavendish Global Health Impact Forum 10/30/2014 10:06:01 AM
Diffusion Pharmaceuticals Clinical Trial Of TSC In Brain Cancer Reaches One Year Interim Endpoint 5/15/2014 9:53:20 AM
Diffusion Pharmaceuticals Closes $5 Million Financing; Completes Enrollment and Dosing in Phase 2 Trial In Brain Cancer 6/20/2013 9:06:59 AM
Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer 12/11/2012 10:16:26 AM
Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial 11/20/2012 9:44:29 AM
1234
//-->